NSMCE1

Summary

NSMCE1 (NSE1 component of SMC5/6 complex, HGNC:29897) is a protein-coding gene on chromosome 16p12.1, encoding Non-structural maintenance of chromosomes element 1 homolog (Q8WV22). RING-type zinc finger-containing E3 ubiquitin ligase that assembles with melanoma antigen protein (MAGE) to catalyze the direct transfer of ubiquitin from E2 ubiquitin-conjugating enzyme to a specific substrate. It is a selective cancer dependency (DepMap: 60.3% of cell lines).

Enables protein dimerization activity and ubiquitin protein ligase activity. Involved in DNA damage response. Located in nucleoplasm. Part of Smc5-Smc6 complex.

Source: NCBI Gene 197370 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 44 total
• Cancer dependency (DepMap): dependent in 60.3% of screened cell lines
• MANE Select transcript: NM_145080

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29897
Approved symbol	NSMCE1
Name	NSE1 component of SMC5/6 complex
Location	16p12.1
Locus type	gene with protein product
Status	Approved
Aliases	NSE1
Ensembl gene	ENSG00000169189
Ensembl biotype	protein_coding
OMIM	617263
Entrez	197370

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 22 protein_coding, 3 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000361439, ENST00000561960, ENST00000562039, ENST00000563273, ENST00000563512, ENST00000563900, ENST00000564342, ENST00000565070, ENST00000565384, ENST00000565626, ENST00000566087, ENST00000567375, ENST00000567710, ENST00000569236, ENST00000869097, ENST00000869098, ENST00000869099, ENST00000869100, ENST00000869101, ENST00000869102, ENST00000869103, ENST00000869104, ENST00000869105, ENST00000933463, ENST00000933464, ENST00000933465, ENST00000933466, ENST00000961548, ENST00000961549, ENST00000961550

RefSeq mRNA: 1 — MANE Select: NM_145080 NM_145080

CCDS: CCDS10628

Canonical transcript exons

ENST00000361439 — 8 exons

Exon	Start	End
ENSE00002599713	27224994	27225236
ENSE00002614980	27268706	27268772
ENSE00003510237	27235178	27235299
ENSE00003516553	27225726	27225846
ENSE00003577604	27233001	27233147
ENSE00003593819	27226720	27226836
ENSE00003601687	27257435	27257581
ENSE00003661547	27234188	27234265

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 96.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 38.5073 / max 509.6753, expressed in 1820 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156834	38.0879	1820
156824	0.3463	95
156825	0.0731	31

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	96.75	gold quality
left testis	UBERON:0004533	96.74	gold quality
kidney epithelium	UBERON:0004819	96.46	gold quality
ganglionic eminence	UBERON:0004023	96.41	gold quality
right adrenal gland	UBERON:0001233	96.37	gold quality
right adrenal gland cortex	UBERON:0035827	96.33	gold quality
right coronary artery	UBERON:0001625	96.27	gold quality
mucosa of transverse colon	UBERON:0004991	96.13	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.13	gold quality
lower esophagus	UBERON:0013473	96.11	gold quality
left adrenal gland	UBERON:0001234	96.05	gold quality
left adrenal gland cortex	UBERON:0035825	96.04	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.03	gold quality
testis	UBERON:0000473	95.88	gold quality
sperm	CL:0000019	95.79	gold quality
adrenal cortex	UBERON:0001235	95.74	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.68	gold quality
popliteal artery	UBERON:0002250	95.57	gold quality
tibial artery	UBERON:0007610	95.56	gold quality
left coronary artery	UBERON:0001626	95.54	gold quality
coronary artery	UBERON:0001621	95.52	gold quality
islet of Langerhans	UBERON:0000006	95.40	gold quality
ventricular zone	UBERON:0003053	95.37	gold quality
aorta	UBERON:0000947	95.22	gold quality
smooth muscle tissue	UBERON:0001135	95.21	gold quality
adrenal gland	UBERON:0002369	95.21	gold quality
mucosa of stomach	UBERON:0001199	95.17	gold quality
upper arm skin	UBERON:0004263	95.08	gold quality
prostate gland	UBERON:0002367	95.06	gold quality
spinal cord	UBERON:0002240	95.02	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	65.75
E-MTAB-8410	yes	9.95
E-MTAB-7606	no	553.61
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

6 targeting NSMCE1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-208A-3P	95.87	66.51	397
HSA-MIR-208B-3P	95.87	66.56	396
HSA-MIR-433-5P	94.67	64.82	99

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 60.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Nse1 RING-like motif is a protein-protein interaction domain required for Smc5-Smc6 holocomplex integrity and recruitment to, or retention at, DNA lesions (PMID:18667531)
• Molecular Insights into the Architecture of the Human SMC5/6 Complex. (PMID:32389690)
• Crucial role of the NSE1 RING domain in Smc5/6 stability and FANCM-independent fork progression. (PMID:38847937)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nsmce1	ENSDARG00000098780
mus_musculus	Nsmce1	ENSMUSG00000030750
rattus_norvegicus	Nsmce1	ENSRNOG00000015218
drosophila_melanogaster	Nse1	FBGN0031848
caenorhabditis_elegans	nse-1	WBGENE00020843

Protein

Protein identifiers

Non-structural maintenance of chromosomes element 1 homolog — Q8WV22 (reviewed: Q8WV22)

All UniProt accessions (7): Q8WV22, H3BN81, H3BR31, H3BR73, H3BSL0, H3BV05, I3L1I3

UniProt curated annotations — full annotation on UniProt →

Function. RING-type zinc finger-containing E3 ubiquitin ligase that assembles with melanoma antigen protein (MAGE) to catalyze the direct transfer of ubiquitin from E2 ubiquitin-conjugating enzyme to a specific substrate. Within MAGE-RING ubiquitin ligase complex, MAGE stimulates and specifies ubiquitin ligase activity likely through recruitment and/or stabilization of the E2 ubiquitin-conjugating enzyme at the E3:substrate complex. Involved in maintenance of genome integrity, DNA damage response and DNA repair. NSMCE3/MAGEG1 and NSMCE1 ubiquitin ligase are components of SMC5-SMC6 complex and may positively regulate homologous recombination-mediated DNA repair. MAGEF1-NSMCE1 ubiquitin ligase promotes proteasomal degradation of MMS19, a key component of the cytosolic iron-sulfur protein assembly (CIA) machinery. Down-regulation of MMS19 impairs the activity of several DNA repair and metabolism enzymes such as ERCC2/XPD, FANCJ, RTEL1 and POLD1 that require iron-sulfur clusters as cofactors.

Subunit / interactions. Component of the SMC5-SMC6 complex which consists at least of SMC5, SMC6, NSMCE2, NSMCE1, NSMCE4A or EID3 and NSMCE3. NSMCE1, NSMCE4A or EID3 and NSMCE3 probably form a subcomplex that bridges the head domains of the SMC5-SMC6 heterodimer. Interacts with NSMCE3. Interacts with MAGEF1.

Subcellular location. Nucleus. Chromosome. Telomere.

Post-translational modifications. Ubiquitinated.

Similarity. Belongs to the NSE1 family.

RefSeq proteins (1): NP_659547* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR002219	PKC_DAG/PE	Domain
IPR011513	Nse1	Family
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR014857	Nse1_RING_C4HC3-type	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily

Pfam: PF07574, PF08746

UniProt features (34 total): helix 11, strand 10, turn 5, region of interest 2, sequence variant 2, chain 1, zinc finger region 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
5WY5	X-RAY DIFFRACTION	2.92
5HVQ	X-RAY DIFFRACTION	2.92
9LWI	ELECTRON MICROSCOPY	3.12
9LWJ	ELECTRON MICROSCOPY	7.19
9LWL	ELECTRON MICROSCOPY	7.25
2CT0	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WV22-F1	89.41	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 251

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-3108214	SUMOylation of DNA damage response and repair proteins

MSigDB gene sets: 186 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_CHROMOSOME_ORGANIZATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_TELOMERE_ORGANIZATION, GOBP_REGULATION_OF_TELOMERE_MAINTENANCE, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_PROTEIN_SUMOYLATION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_REGULATION_OF_CHROMOSOME_ORGANIZATION, GOBP_RECOMBINATIONAL_REPAIR, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, GOCC_SPINDLE

GO Biological Process (7): double-strand break repair via homologous recombination (GO:0000724), DNA damage response (GO:0006974), protein sumoylation (GO:0016925), regulation of telomere maintenance (GO:0032204), chromatin looping (GO:0140588), DNA repair (GO:0006281), DNA recombination (GO:0006310)

GO Molecular Function (7): ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), protein dimerization activity (GO:0046983), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (7): chromosome, centromeric region (GO:0000775), chromosome, telomeric region (GO:0000781), nucleus (GO:0005634), nucleoplasm (GO:0005654), Smc5-Smc6 complex (GO:0030915), mitotic spindle pole (GO:0097431), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
SUMO E3 ligases SUMOylate target proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	2
chromosomal region	2
recombinational repair	1
double-strand break repair	1
cellular response to stress	1
peptidyl-lysine modification	1
protein modification by small protein conjugation	1
telomere maintenance	1
regulation of chromosome organization	1
regulation of DNA metabolic process	1
chromatin organization	1
DNA damage response	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
protein binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
condensed chromosome	1
SUMO ligase complex	1
spindle pole	1
mitotic spindle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1068 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NSMCE1	NSMCE4A	Q9NXX6	803
NSMCE1	NSMCE2	Q96MF7	795
NSMCE1	SMC6	Q96SB8	788
NSMCE1	NSMCE3	Q96MG7	673
NSMCE1	SMC5	Q8IY18	667
NSMCE1	SLF1	Q9BQI6	593
NSMCE1	MAGEB18	Q96M61	435
NSMCE1	DCAF1	Q9Y4B6	433
NSMCE1	STYK1	Q6J9G0	431
NSMCE1	SLF2	Q8IX21	428
NSMCE1	RNF151	Q2KHN1	396
NSMCE1	HLTF	Q14527	391
NSMCE1	STPG4	Q8N801	391
NSMCE1	MAIP1	Q8WWC4	389
NSMCE1	RNF168	Q8IYW5	379

IntAct

59 interactions, top by confidence:

A	B	Type	Score
NSMCE3	NSMCE1	psi-mi:“MI:0915”(physical association)	0.970
NSMCE3	NSMCE1	psi-mi:“MI:0407”(direct interaction)	0.970
NSMCE1	NSMCE3	psi-mi:“MI:0407”(direct interaction)	0.970
NSMCE3	NSMCE1	psi-mi:“MI:0914”(association)	0.970
NSMCE1	NSMCE3	psi-mi:“MI:0915”(physical association)	0.970
NSMCE1	NSMCE3	psi-mi:“MI:0403”(colocalization)	0.970
SMC6	SMC5	psi-mi:“MI:0914”(association)	0.860
EID3	NSMCE1	psi-mi:“MI:0915”(physical association)	0.830
EID3	NSMCE1	psi-mi:“MI:0914”(association)	0.830
NSMCE3	EID3	psi-mi:“MI:0914”(association)	0.820
SMC6	NSMCE1	psi-mi:“MI:0915”(physical association)	0.810
NSMCE1	SMC6	psi-mi:“MI:0915”(physical association)	0.810
NSMCE1	SMC5	psi-mi:“MI:0914”(association)	0.760
NSMCE1	SMC5	psi-mi:“MI:0915”(physical association)	0.760
EID3	SMC5	psi-mi:“MI:0915”(physical association)	0.740
NSMCE4A	NSMCE1	psi-mi:“MI:0914”(association)	0.740
NSMCE1	NSMCE2	psi-mi:“MI:0914”(association)	0.710
NSMCE3	PJA1	psi-mi:“MI:0914”(association)	0.710
ZNF597	TASOR2	psi-mi:“MI:0914”(association)	0.640

BioGRID (125): SMC6 (Affinity Capture-MS), NSMCE2 (Affinity Capture-MS), NDNL2 (Affinity Capture-MS), SMC5 (Affinity Capture-MS), PMF1 (Affinity Capture-MS), SIMC1 (Affinity Capture-MS), FAM178A (Affinity Capture-MS), NSMCE4A (Affinity Capture-MS), NSMCE1 (Affinity Capture-MS), NSMCE1 (Affinity Capture-MS), NSMCE1 (Affinity Capture-MS), NDNL2 (Co-fractionation), NSMCE1 (Co-fractionation), SMC5 (Co-fractionation), SMC6 (Co-fractionation)

ESM2 similar proteins: O01757, O13873, O42857, O60072, O74462, O74967, O94553, O94663, P32910, P36617, P40555, P41810, P53914, P87157, P87303, P91529, Q02939, Q09760, Q10410, Q12483, Q19555, Q2TBL4, Q3T0X7, Q499U6, Q54NQ0, Q54S43, Q5RAZ5, Q6BGW8, Q6BZX4, Q6CLR2, Q6FM46, Q6FP41, Q6FWT4, Q75B51, Q84K16, Q86JM3, Q8WV22, Q9BUI4, Q9C106, Q9D483

Diamond homologs: Q3T0X7, Q499U6, Q53EK2, Q5RAZ5, Q6DGT7, Q6P881, Q6PAF4, Q8WV22, Q9D720, Q9VMA0

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	NSMCE1	ubiquitination
NSMCE1	“form complex”	SMC5/6	binding
NSMCE3	“up-regulates activity”	NSMCE1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of DNA damage response and repair proteins	8	50.9×	3e-10

GO biological processes:

GO term	Partners	Fold	FDR
regulation of telomere maintenance	6	168.5×	8e-11
protein sumoylation	6	64.8×	2e-08
double-strand break repair via homologous recombination	8	41.6×	9e-10
DNA damage response	6	10.7×	5e-04
DNA repair	5	10.6×	2e-03
protein ubiquitination	5	6.9×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1799 predictions. Top by Δscore:

Variant	Effect	Δscore
16:27225724:A:AC	donor_gain	1.0000
16:27225725:C:CC	donor_gain	1.0000
16:27226832:TCCTT:T	acceptor_gain	1.0000
16:27226833:CCTTC:C	acceptor_gain	1.0000
16:27226834:CTT:C	acceptor_gain	1.0000
16:27226836:TCTGC:T	acceptor_loss	1.0000
16:27226837:C:CC	acceptor_gain	1.0000
16:27226837:CTG:C	acceptor_loss	1.0000
16:27232996:AGTAC:A	donor_loss	1.0000
16:27232997:GTACC:G	donor_loss	1.0000
16:27232998:TA:T	donor_loss	1.0000
16:27232999:ACCTC:A	donor_loss	1.0000
16:27233000:C:CG	donor_loss	1.0000
16:27233050:T:TA	donor_gain	1.0000
16:27233143:TCCAG:T	acceptor_gain	1.0000
16:27233144:CCAG:C	acceptor_gain	1.0000
16:27233144:CCAGC:C	acceptor_gain	1.0000
16:27233145:CAG:C	acceptor_gain	1.0000
16:27233145:CAGC:C	acceptor_gain	1.0000
16:27233146:A:T	acceptor_gain	1.0000
16:27233146:AG:A	acceptor_gain	1.0000
16:27233147:GCTGG:G	acceptor_loss	1.0000
16:27233148:C:CC	acceptor_gain	1.0000
16:27233148:C:T	acceptor_loss	1.0000
16:27234186:A:AC	donor_gain	1.0000
16:27234186:ACAG:A	donor_gain	1.0000
16:27234186:ACAGC:A	donor_gain	1.0000
16:27234187:C:CC	donor_gain	1.0000
16:27234187:CAG:C	donor_gain	1.0000
16:27234187:CAGC:C	donor_gain	1.0000

AlphaMissense

1778 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:27233008:A:G	L159P	0.999
16:27225744:A:G	W235R	0.998
16:27225744:A:T	W235R	0.998
16:27225765:A:G	C228R	0.998
16:27225804:A:G	C215R	0.998
16:27226748:C:T	C191Y	0.998
16:27226749:A:G	C191R	0.998
16:27233012:A:G	W158R	0.998
16:27233012:A:T	W158R	0.998
16:27225837:A:G	C204R	0.997
16:27226747:G:C	C191W	0.997
16:27233098:A:T	I129K	0.997
16:27257524:C:G	R16P	0.997
16:27225742:C:A	W235C	0.996
16:27225742:C:G	W235C	0.996
16:27225764:C:G	C228S	0.996
16:27225765:A:T	C228S	0.996
16:27225802:G:C	C215W	0.996
16:27225803:C:G	C215S	0.996
16:27225804:A:T	C215S	0.996
16:27225836:C:T	C204Y	0.996
16:27233035:A:G	L150P	0.996
16:27257515:A:G	L19P	0.996
16:27225803:C:T	C215Y	0.995
16:27226738:A:C	C194W	0.995
16:27226748:C:A	C191F	0.995
16:27226748:C:G	C191S	0.995
16:27226749:A:T	C191S	0.995
16:27233095:A:G	L130S	0.995
16:27233098:A:C	I129R	0.995

dbSNP variants (sampled 300 via entrez): RS1000007600 (16:27268950 C>T), RS1000103418 (16:27269234 C>G), RS1000142522 (16:27270291 C>A,G,T), RS1000157953 (16:27243843 G>A,C), RS1000169719 (16:27235790 G>A), RS1000235931 (16:27233128 G>A), RS1000236847 (16:27262968 G>C), RS1000351822 (16:27264529 T>C), RS1000413472 (16:27227161 G>A), RS1000455992 (16:27231453 A>G), RS1000573565 (16:27262973 A>T), RS1000804461 (16:27255989 T>C,G), RS1000807504 (16:27237743 T>A,C), RS1000842789 (16:27238224 C>T), RS1000926019 (16:27243069 G>A)

Disease associations

OMIM: gene MIM:617263 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST003542_67	Night sleep phenotypes	4.000000e-06
GCST003875_18	Gut microbiota (bacterial taxa)	2.000000e-09
GCST004482_117	Peripheral arterial disease (traffic-related air pollution interaction)	4.000000e-08
GCST007732_9	Allergic disease (asthma, hay fever or eczema)	5.000000e-06
GCST007941_30	Medication use (adrenergics, inhalants)	3.000000e-08
GCST008916_121	Asthma	2.000000e-17
GCST008916_3	Asthma	1.000000e-12
GCST009798_29	Asthma	3.000000e-08
GCST009798_58	Asthma	3.000000e-09
GCST009798_64	Asthma	4.000000e-17
GCST009798_67	Asthma	5.000000e-11

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0007827	nighttime rest measurement
EFO:0007874	gut microbiome measurement
EFO:0007883	taxonomic microbiome measurement
EFO:0007908	traffic air pollution measurement
EFO:0009941	Inhalant adrenergic use measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
TAK-243	increases sumoylation	1
bufotalin	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
CPG-oligonucleotide	decreases expression	1
ICG 001	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Dexamethasone	increases expression, affects cotreatment	1
Dimethyl Sulfoxide	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Thiram	decreases expression	1
Tunicamycin	increases expression	1
Urethane	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.